Copyright
©The Author(s) 2016.
World J Clin Oncol. Apr 10, 2016; 7(2): 149-154
Published online Apr 10, 2016. doi: 10.5306/wjco.v7.i2.149
Published online Apr 10, 2016. doi: 10.5306/wjco.v7.i2.149
Figure 2 Different sequential alternatives to be used in advanced pancreatic neuroendocrine tumor patients based on approved agents.
The term “chemotherapy” may include streptozocin ± 5-fluorouracil or doxorubicin, or temozolomide ± capecitabine.
- Citation: Grande E. Sequential treatment in disseminated well- and intermediate-differentiated pancreatic neuroendocrine tumors: Common sense or low rationale? World J Clin Oncol 2016; 7(2): 149-154
- URL: https://www.wjgnet.com/2218-4333/full/v7/i2/149.htm
- DOI: https://dx.doi.org/10.5306/wjco.v7.i2.149